By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The Moroccan population is becoming increasingly aware of the importance of healthcare. This is leading to increased demand for pharmaceuticals.
Patented medicines represented 41.2% of the total market and 58.1% of the prescription one, but this part would decrease in the coming years due to encouragement of generics and (very recently) biosimilars, because their prescription is strongly supported by the Moroccan government.
The Moroccan government is revising its regulatory framework to align with international standards. This creates a more transparent and predictable environment for pharmaceutical companies.
Technologies like e-commerce, online pharmacies, and telemedicine are gaining traction in Morocco. This presents opportunities for companies to develop innovative distribution channels and reach a wider customer base.
According to Business Monitor International (BMI) study, currently generics and biosimilars cover 80-90% of the public medicines market and only 25% of the private one. The OTC sector would undergo the same competition from generics, and is expected to decrease its share up to 22.8% in 2026.
Currently pharmaceutical sales represent approx. 1,47% of Morocco’s GDP and 24.4% of the total health expenditure of the African countries.
According to AMIP, the local pharmaceutical production covers 65% of the internal pharmaceutical market, while 10% is intended for export. A great part of active pharmaceutical ingredients are imported from abroad, says BMI.
The pharmaceutical manufacturing industry is growing in Morocco. Numerous regional pharmaceutical firms manufacture a vast array of goods, such as generic medications, medical equipment, and vaccines.
There are three professional associations in the country representing the different industries, i.e. the Moroccan Association of Pharmaceutical Industry (AMIP), Les enterprises du medicament au Maroc (LEMM) of multi-national companies and the Moroccan Association of Generic Medicines (AMMG).
As reported by the Association of the Pharmaceutical Industry, the Moroccan National Laboratory for the Control of Medicines (LNCM) has been certified both by the World Health Organization and the European Directorate for the Quality of Medicines, thus acknowledging the quality of the production run under GMP conditions.
The majority of generic medicines present on the Moroccan market are locally produced, while Africa and the Middle East are the preferred areas of export (counting for 8% of the generics’ production).
Regulatory procedures are under the control of the Drugs and Pharmaceutical Directorate of the Ministry of Health. The latter is divided into three sub directions: firstly, the Division of Pharmacy, secondly, the Pharmaceutical sector monitoring department and finally, the LNCM which is responsible for the quality review of pharmaceutical documentations as well as of lab-testings.
The nation’s reliance on pharmaceutical imports has decreased as a result of this indigenous production.
Although Morocco has increased its ability to produce pharmaceuticals, it still imports some of these goods, particularly specialized medications and raw ingredients. These imports aid in meeting the need for a wide range of healthcare products.
With a network of pharmacies and medical facilities serving the populace, Morocco has a well-organized system for distributing pharmaceutical items. A wide range of people have access to medications due to the public and private pharmaceutical distribution systems.
The Morocco pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Boron Morocco: Introduced “Oscillo coccineum 1000 doses,” a high-dose homeopathic medication for influenza-like symptoms. Oscillo coccineum reduces the duration and severity of flu symptoms such as body aches, headache, fever, chills, and fatigue.
Mead Pharma Morocco: Launched “Voltaire Emulex,” a topical pain relief gel. Voltaire Emulex Extra Strength contains the non-steroidal anti-inflammatory drug (NSAID), diclofenac dimethylamine. Diclofenac dimethylamine works to relieve pain and reduce inflammation (swelling).
Sanofi Morocco: Launched “Toujeo Solostar,” a long-acting insulin analog for diabetes management. Toujeo Solostar is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.
GlaxoSmithKline (GSK) Morocco: Introduced “Seretide Discus,” a combination inhaler for asthma and COPD treatment. It is a fixed dose combination of salmeterol and fluticasone propionate for use in patients with asthma and chronic.
